-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;6:106-130.
-
(2006)
CA Cancer J Clin
, vol.6
, pp. 106-130
-
-
Jemal, A.1
Murray, T.2
Samuels, A.3
-
2
-
-
0036251451
-
Global increases in kidney cancer incidence, 1973-1992
-
Mathew A, Devesa SS, Fraumeni JF Jr, et al. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev. 2002;11:171-178.
-
(2002)
Eur J Cancer Prev
, vol.11
, pp. 171-178
-
-
Mathew, A.1
Devesa, S.S.2
Fraumeni Jr, J.F.3
-
3
-
-
28844484134
-
Medical progress: Renal-cell carcinoma
-
Cohen HT, McGovern FJ. Medical progress: renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
-
(2005)
N Engl J Med
, vol.353
, pp. 2477-2490
-
-
Cohen, H.T.1
McGovern, F.J.2
-
4
-
-
0041691157
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal Cancer
-
Stadler WM, Huo D, George C, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal Cancer. J Urol. 2003;170:1141-1145.
-
(2003)
J Urol
, vol.170
, pp. 1141-1145
-
-
Stadler, W.M.1
Huo, D.2
George, C.3
-
5
-
-
0034113335
-
Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
-
Motzer RJ, Mazumdar M, Bacik J, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928-1935.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1928-1935
-
-
Motzer, R.J.1
Mazumdar, M.2
Bacik, J.3
-
6
-
-
0033847587
-
Long-term survival update for high-dose recombinant interleukin-2 patients with renal cell carcinoma
-
Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 patients with renal cell carcinoma. Cancer J Sci Am. 2000;1(Suppl 6):S55-S57.
-
(2000)
Cancer J Sci Am
, vol.1
, Issue.SUPPL. 6
-
-
Fisher, R.I.1
Rosenberg, S.A.2
Fyfe, G.3
-
7
-
-
0038016523
-
Thalidomide therapy for renal cell carcinoma
-
Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol. 2003;46:59-65.
-
(2003)
Crit Rev Oncol Hematol
, vol.46
, pp. 59-65
-
-
Amato, R.J.1
-
8
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
9
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
10
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci T, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, T.2
Tomczak, P.3
-
11
-
-
33846821872
-
Targeted therapy for metastatic renal cell carcinoma
-
Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601-5608.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5601-5608
-
-
Motzer, R.J.1
Bukowski, R.M.2
-
12
-
-
0033532557
-
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
-
Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg Med Chem Lett. 1999;9:1625-1630.
-
(1999)
Bioorg Med Chem Lett
, vol.9
, pp. 1625-1630
-
-
Muller, G.W.1
Chen, R.2
Huang, S.Y.3
-
13
-
-
0033168605
-
Differential cytokine mod- ulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
-
Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine mod- ulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163: 380-386.
-
(1999)
J Immunol
, vol.163
, pp. 380-386
-
-
Corral, L.G.1
Haslett, P.A.J.2
Muller, G.W.3
-
14
-
-
20144375457
-
Orally administered lenalido-mide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
-
Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalido-mide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69: 56-63.
-
(2005)
Microvasc Res
, vol.69
, pp. 56-63
-
-
Dredge, K.1
Horsfall, R.2
Robinson, S.P.3
-
15
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
16
-
-
67650047103
-
-
National Cancer Institute: Common Terminology Criteria for Adverse Events NCI CTCAE, Version 3.0; 2006
-
National Cancer Institute: Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0; 2006.
-
-
-
-
17
-
-
0042343801
-
A randomized trial of bevaci-zumab, an anti-vascular endothelial growth factory antibody, for metastatic renal Cancer
-
Yang JC, Haworth L, Sperry RV, et al. A randomized trial of bevaci-zumab, an anti-vascular endothelial growth factory antibody, for metastatic renal Cancer. N Engl J Med. 2003;349:427-434.
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sperry, R.V.3
-
18
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
Motzer R, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.
-
(2002)
J Clin Oncol
, vol.20
, pp. 289-296
-
-
Motzer, R.1
Bacik, J.2
Murphy, B.A.3
-
19
-
-
33751565011
-
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
-
Choueiri TK, Dreicer R, Rini BI, et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer. 2006;107:2609-2616.
-
(2006)
Cancer
, vol.107
, pp. 2609-2616
-
-
Choueiri, T.K.1
Dreicer, R.2
Rini, B.I.3
-
20
-
-
0035412366
-
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
-
Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
-
(2001)
Blood
, vol.98
, pp. 210-216
-
-
Davies, F.E.1
Raje, N.2
Hideshima, T.3
-
21
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
-
22
-
-
23844455555
-
Final findings from a phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
-
Abstract 4544
-
Raitan MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2005;23:388[Abstract 4544].
-
(2005)
Proc Am Soc Clin Oncol
, vol.23
, pp. 388
-
-
Raitan, M.J.1
Eisen, T.2
Stadler, W.M.3
-
23
-
-
33748614966
-
Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
-
Abstract 4524
-
Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol. 2006;24:18S(Abstract 4524).
-
(2006)
J Clin Oncol
, vol.24
-
-
Eisen, T.1
Bukowski, R.M.2
Staehler, M.3
-
25
-
-
84869379519
-
-
Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2006;24(June 20 Supplement) (Abstract LBA3).
-
Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I. 2006;24(June 20 Supplement) (Abstract LBA3).
-
-
-
|